Lexaria Bioscience (LEXX) said Wednesday it received approval from the lead clinical site's human research ethics committee to begin dosing in its phase 1b, 12-week chronic study of GLP-1-H24-4 for diabetes and weight loss.
The study will feature five arms testing various DehydraTECH formulations including CBD capsules, semaglutide capsules, semaglutide combined with CBD capsules, Rybelsus tablets as control, and optional tirzepatide capsules, the company said.
Clinical test article manufacturing for all study arms is complete, with a first patient, first dose study milestone slated to be achieved in late December or January 2025, Lexaria said.
The study will take place across seven clinical sites in Australia and is expected to be recognized by the US Food and Drug Administration as a registrational phase 1b study, the company said.
Shares of Lexaria were up 3.9% in recent Wednesday trading.
Price: 2.39, Change: +0.09, Percent Change: +3.91
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.